Data for (Study ST002948)
(Analysis AN004835)Values for each metabolite have been scaled by dividing by the mean across all factors Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study| Metabolite | F1 | F2 | F3 | F4 | F5 | F6 |
|---|---|---|---|---|---|---|
| Arachidonic acid | 1.0202 | 0.9380 | 0.9399 | 0.9636 | 1.1066 | 0.9648 |
| Bilirubin | 1.0910 | 0.7973 | 1.0399 | 1.0845 | 1.0618 | 0.7377 |
| Lactic acid | 1.0118 | 1.0130 | 0.9793 | 1.1538 | 0.9990 | 0.8531 |
| Lauric acid | 0.9793 | 0.7927 | 0.9240 | 1.1604 | 1.1212 | 0.9978 |
| LPC 14:0 | 1.0256 | 1.1100 | 0.9457 | 1.0566 | 0.9590 | 0.9726 |
| LPC 16:0 | 1.0317 | 1.0281 | 0.9718 | 1.0769 | 0.9798 | 0.9282 |
| LPC 17:0 | 1.0454 | 1.0002 | 1.0029 | 1.0380 | 0.9633 | 0.9385 |
| LPC 17:1 | 1.0656 | 1.0136 | 1.0044 | 1.0488 | 0.9296 | 0.9420 |
| LPC 18:0 | 1.0364 | 1.0372 | 0.9804 | 1.1200 | 0.9466 | 0.9160 |
| LPC 18:1 | 1.0671 | 0.9817 | 1.0210 | 1.0717 | 0.9285 | 0.9171 |
| LPC 18:1 d7 | 0.9887 | 1.0231 | 1.0024 | 1.0108 | 0.9956 | 0.9927 |
| LPC 19:0 | 1.0179 | 0.8649 | 1.0866 | 1.3048 | 0.8978 | 0.8256 |
| LPE 18:0 | 1.0140 | 1.0339 | 0.9526 | 1.0945 | 0.9918 | 0.9550 |
| LPI 20:4 | 1.0840 | 1.0005 | 1.0230 | 1.0084 | 0.9702 | 0.8413 |
| Oleamide | NA | NA | NA | NA | NA | NA |
| Oleic acid | 0.9708 | 0.8596 | 0.9991 | 0.9815 | 1.0530 | 1.1131 |
| Palmitic acid d31 | 0.9884 | 1.0207 | 1.0160 | 1.0014 | 0.9913 | 0.9864 |
| Palmitoleic acid | 0.8889 | 0.8198 | 0.9493 | 0.9864 | 1.1026 | 1.3123 |
| Pyruvic acid | 1.0951 | 0.9701 | 0.9888 | 1.0575 | 0.9685 | 0.8730 |
| Sphingosine | 1.1962 | 0.8751 | 1.0606 | 1.6752 | 0.7470 | 0.4423 |
| Sphingosine-1-Phosphate | 1.0841 | 0.9762 | 0.9587 | 0.9367 | 1.0501 | 0.9013 |
| Sphingosine d7 | 0.9859 | 1.0267 | 0.9993 | 1.0122 | 0.9897 | 1.0112 |
Factors:
| F1 | Time:T0 | Treatment:Mepolizumab |
| F2 | Time:T0 | Treatment:Omalizumab |
| F3 | Time:T1 | Treatment:Mepolizumab |
| F4 | Time:T1 | Treatment:Omalizumab |
| F5 | Time:T2 | Treatment:Mepolizumab |
| F6 | Time:T2 | Treatment:Omalizumab |